Checked Sep 2026
·
Pinnacle Peptides
Supplements & Nutrition
Lakewood
The FDA does not approve dietary supplements before they are sold. The agency says so in those exact words, and that single fact explains most of what is confusing about this category. It also makes the agency's position on particular ingredients worth knowing: SARMs cannot be legally marketed in the US as a dietary supplement or as a drug. Protein powder runs $25 to $70 a tub.
| Service | Typical |
|---|---|
| Protein powderNational range | $25 to $70 per 2 lb tub |
| Private-label supplement manufacturingNational range | $3 to $10 per bottle at a 5,000-unit run |
Ranges last checked September 2026. They come down automatically when they are due to be rechecked.
Every figure above comes from a named source we can link to, with the date we last checked it. We publish ranges rather than single prices because a range is what a provider will actually give you: the same job moves with what is being worked on, the materials, how hard it is to get at and how busy the trade is locally. Treat these as the order of magnitude to expect before you call, not as a quote.
The figures here are national. Where a source publishes figures state by state, the state pages carry that local figure instead of this one. We do not scale a national number by a multiplier of our own invention.
Every range carries a review date. When that date passes the number comes down until it is rechecked, rather than sitting here undated.
The FDA states it directly: it does not have the authority to approve dietary supplements before they are marketed. Under the Dietary Supplement Health and Education Act of 1994, manufacturers and distributors carry the initial responsibility for ensuring their products meet the safety standards. The agency's role is after the fact.
So a product described as FDA approved is misusing the term, and there is no such thing to look for. What does exist is 21 CFR Part 111, the current good manufacturing practice rules, which require a manufacturer to ensure the identity, purity, quality, strength and composition of what they make, and that the product contains what the label says and is not contaminated. Compliance with those rules is not approval, and it is verified by inspection rather than by certificate.
A structure or function claim describes how an ingredient affects normal body structure or function. Supports healthy bones is one. Those do not require pre-approval, but the manufacturer must notify the FDA within thirty days of first marketing the claim, and the label must carry a specific disclaimer in these words: this statement has not been evaluated by the Food and Drug Administration, this product is not intended to diagnose, treat, cure, or prevent any disease.
A disease claim is different and requires FDA authorization before marketing. A product that says it treats or prevents a condition, without that authorization, is making a claim the law does not permit, and the disclaimer does not cure it.
So the practical test on a label is not whether the disclaimer is present. It is whether the claims around the disclaimer stay on the structure and function side of the line.
Selective androgen receptor modulators are sold labeled as dietary supplements and as research chemicals. The FDA's published position is that they are not approved and cannot be legally marketed in the United States as a dietary supplement or as a drug at this time.
The risks the agency names are not minor: heart attack or stroke, psychosis and hallucinations, liver injury and acute liver failure, testicular shrinkage, infertility and miscarriage.
This is a live enforcement position rather than an old statement. In December 2025 the FDA issued a warning letter treating a seller's SARM products as unapproved new drugs that are not generally recognized as safe and effective, under sections 505(a), 301(d), 201(g)(1) and 201(p) of the Federal Food, Drug, and Cosmetic Act.
The same pattern applies to peptides sold with a disclaimer saying they are not for human consumption. In a warning letter dated 31 March 2026 concerning retatrutide and tirzepatide, the FDA wrote that despite statements on the labeling marketing the products for research use only, and not intended for human consumption, medical use or veterinary use, evidence obtained from the seller's website established that the products are intended to be drugs for human use. The legal basis was the same: unapproved new drugs.
What the label says about intended use is not the end of the question. What the seller's own marketing says about it is evidence of the real one.
One limit on what this page will assert. The FDA warning letter read here names retatrutide and tirzepatide specifically. No FDA statement was found declaring other commonly sold peptides unlawful dietary ingredients, and the agency's ingredient directory carries no peptide entries at all. So this page does not claim the FDA has ruled on peptides in general, because it has not been shown to have done so. It has ruled on how a seller markets them.
Stop looking for FDA approval. It does not exist for this category, and a seller invoking it is telling you something.
Read the claims rather than the disclaimer. A disclaimer sitting under a claim to treat or prevent a condition does not make that claim lawful.
Ask for a certificate of analysis for the specific batch, not a generic one. Manufacturers pay $500 to $2,000 a batch for these, which means a serious operation has them.
Treat research use only labeling as a warning rather than a technicality. The FDA has said in terms that it does not decide what a product is.
On SARMs, understand what you are being sold. The agency's position is that they cannot lawfully be marketed as a supplement or a drug, and its list of associated harms is long and serious.
No. The FDA states it does not have the authority to approve dietary supplements before they are marketed. Under the 1994 Act, manufacturers and distributors carry the initial responsibility for safety, and the agency's role is after the fact.
It is required wording on a structure or function claim: this statement has not been evaluated by the Food and Drug Administration, this product is not intended to diagnose, treat, cure, or prevent any disease. Its presence does not make a disease claim lawful.
A structure or function claim describes an effect on normal body structure or function and needs no pre-approval, only notification to the FDA within thirty days. A disease claim requires FDA authorization before marketing.
No. The FDA states that SARMs are not approved and cannot be legally marketed in the US as a dietary supplement or a drug. It issued a warning letter in December 2025 treating a seller's SARM products as unapproved new drugs.
Heart attack or stroke, psychosis and hallucinations, liver injury and acute liver failure, testicular shrinkage, infertility and miscarriage.
No. In a March 2026 warning letter the FDA wrote that despite research use only statements, evidence from the seller's own website established the products were intended to be drugs for human use.
Not that this page can show. The warning letter read here names retatrutide and tirzepatide, and the FDA's ingredient directory carries no peptide entries. This page does not claim more than the sources support.
A certificate of analysis for the specific batch, and who did the testing. Manufacturers pay $500 to $2,000 a batch for those, so a serious operation has them.